ARTICLE | Company News
Oncologix Inc. deal
May 23, 1994 7:00 AM UTC
The Gaithersburg, Md., company acquired worldwide exclusive rights to a cancer therapy adjunct from Boehringer Ingelheim (Germany). The drug, OLX-102, will be the first agent taken by Oncologix into the clinic.
Two published trials in 989 patients have shown that the drug, mopidamol, can increase survival in cancer patients, Oncologix said. At least one Phase III trial is planned for 1995. ...